SSC
DNTH icon

Spruce Street Capital’s Dianthus Therapeutics DNTH Stock Holding History

Spruce Street Capital’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.6M Sell
354,816
-18,458
-5% -$1.61M 6.79% 6
2026
Q1 		$31.3M Buy
373,274
+75,837
+25% +$4.39M 7.53% 4
2025
Q4 		$12.3M Buy
+297,437
New +$11.5M 4.05% 10

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Spruce Street Capital's DNTH Position: Q2 2026 in Review

Spruce Street Capital reduced its Dianthus Therapeutics (DNTH) stake by 4.9% in Q2 2026, selling an estimated $1.61M and leaving 354,816 shares worth $34.6M. The position accounts for 6.79% of the portfolio, ranked #6.

Spruce Street Capital first reported a position in DNTH in Q4 2025 and has held it in 3 quarters since. 268 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • Spruce Street Capital held 354,816 shares of Dianthus Therapeutics worth $34.6M as of Q2 2026.
  • Spruce Street Capital sold 18,458 Dianthus Therapeutics shares in Q2 2026, an estimated $1.61M.
  • Dianthus Therapeutics made up 6.79% of Spruce Street Capital's portfolio in Q2 2026, its #6 holding.
  • Spruce Street Capital first reported a position in Dianthus Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 268 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Spruce Street Capital's 13F filing for Q2 2026, filed 13 Aug 2026.